// App-Quantinova.ai

4802 : PB1, a DDR2 inhibitor with antitumor activity in preclinical models of squamous cell carcinoma and KRAS-mutated adenocarcinoma of the lung

Researchers

Presenter

  • Silvia Garcia-Roman

Principal Investigators

  • Miguel Angel Molina

  • Jose Ignacio Borrell

  • Raimon Puig de la Bellacasa

  • Daniela Morales

  • Jordi Bertran

  • Ana Gimenez

  • Niki Karachaliou

  • Rafael Rosell

Medical Centers

  • Pangaea Biotech, Barcelona, Spain

  • Institut Quimic de Sarria (IQS), Barcelona, Spain

  • Instituto Oncologico Dr. Rosell, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Squamous cell carcinoma

  • Brain cancer

  • Solid malignancies

Biomarkers

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • Hepatocyte growth factor receptor

  • Serpin B3

  • Solute Carrier Family 22 Member 3

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • dasatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved